On September 2, 2021 ChemoCentryx, Inc., (Nasdaq: CCXI), reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences (Press release, ChemoCentryx, SEP 2, 2021, View Source [SID1234587194]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2021 Virtual Wells Fargo Healthcare Conference
Fireside Chat Thursday, September 9 at 4:40 p.m. Eastern Time
H.C. Wainwright 23rd Annual Global Investment Conference
On-demand presentation available beginning Monday, September 13 at 7:00 a.m. Eastern Time
Live audio webcasts of the Wells Fargo fireside chat, as well as the on-demand H.C. Wainwright presentation can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. Replays of both the Wells Fargo and H.C. Wainwright presentations will be available on the Company’s website for two weeks following the respective presentation dates.

On September 2, 2021 Blueprint Medicines Corporation (NASDAQ: BPMC) reported that Kate Haviland, Blueprint Medicines’ Chief Operating Officer, and Fouad Namouni, M.D., Blueprint Medicines’ President, Research & Development, will participate virtually in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 12:30 p.m. ET (Press release, Blueprint Medicines, SEP 2, 2021, View Source [SID1234587193]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines’ website at View Source A replay of the webcast will be archived on Blueprint Medicines’ website for 30 days following the presentation.

On September 2, 2021 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in three upcoming virtual investor conferences (Press release, Harpoon Therapeutics, SEP 2, 2021, View Source [SID1234587191]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A panel discussion ("Large Molecule Drugs for Oncology – Framing the Tip of the Spear for Novel Antibodies and Protein Therapeutics") at Citi’s 16th Annual BioPharma Conference on Thursday, September 9, 2021 at 1:25 p.m. ET / 10:25 a.m. PT;

A fireside chat at Baird’s 2021 Global Healthcare Conference on Wednesday, September 15, 2021 at 3:10 p.m. ET / 12:10 p.m. PT; and

A fireside chat at Cantor’s 2021 Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 2 p.m. ET / 11 a.m. PT.
Live webcasts from the Citi and Cantor conference events will be available from the Events and Presentations section of the company’s website at View Source and will be archived there shortly after the events.

On September 2, 2021 Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, reported members of the executive team will participate in the following upcoming virtual investor conferences (Press release, Kezar Life Sciences, SEP 2, 2021, View Source [SID1234587190]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Virtual Healthcare Conference
Thursday, September 9, 2021, 4:00 PM ET
Presenter: John Fowler, Chief Executive Officer, and Noreen Roth Henig, M.D., Chief Medical Officer

H. C. Wainwright 23rd Annual Global Investment Conference
Monday, September 13, 2021, 7:00 AM ET
Presenter: John Fowler, Chief Executive Officer

A webcast of both presentations may be accessed at the "Events & Presentations" section of Kezar’s website at View Source Kezar Life Sciences will maintain an archived replay of the webcasts on its website for 90 days after the conferences.

On September 2, 2021 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that management will participate in three upcoming virtual investor conferences (Press release, Autolus, SEP 2, 2021, View Source [SID1234587189]). An audio webcast of any presentations will be available live. You can access the webcasts via the Events section of the Autolus website. An archived version will also be available through the Company’s website for a limited time following the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!